Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum macrophage migration inhibitory factor levels in Hashimoto’s thyroiditis

The Egyptian Journal of Internal Medicine volume 31, pages 31–37 (2019)Cite this article

Abstract

Background

Hashimoto’s thyroiditis (HT) is the most common autoimmune thyroid disease. The actual mechanism by which the immunological factors lead to HT has remained obscure. Macrophage migration inhibitory factor (MIF) is recently recognized as a cytokine that has a broad range of inflammatory and immune effects. The aim of this study is to assess the role of MIF in the pathogenesis of HT.

Patients and methods

One hundred and twenty-nine patients were classified into three groups: (a) overt hypothyroidism, (b) subclinical hypothyroidism, and (c) the control group. A complete history taking, clinical examination, and laboratory investigations were done. Laboratory investigations included thyroid function tests [thyroid-stimulating hormone (TSH), triiodothyronine, and thyroxine], antithyroid antibodies (antithyroid peroxidase antibodies and thyroglobulin antibodies), and MIF level.

Results

There is highly statistically significant difference between the three groups regarding MIF, the highest level being in group 1>group 2>group 3. In both hypothyroid groups (1 and 2), there are statistically significant positive correlations between MIF with TSH, thyroid peroxidase antibodies, and thyroglobulin antibodies, but there is no statistically significant correlation between MIF with thyroid functions tests and antithyroid antibodies in the control group.

Conclusion

Serum MIF levels increased in overt and subclinical hypothyroidism and its levels were positively correlated to TSH and thyroid-specific autoantibodies. Serum MIF levels play a role in the pathogenesis of thyroid autoimmune responses in patients with HT. We recommend further larger studies to assess the MIF role in the prognosis of the HT and its treatment by a new strategy.

References

  1. Brent GA, Davies TF. Hypothyroidism and thyroiditis. In: ed. Williams textbook of endocrinology. 12th 2012. Philadelphia, PA: XXXX. 423–456.

  2. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014; 13:391–397.

    Article  CAS  Google Scholar 

  3. Cox GM, Kithcart AP, Pitt D, Guan Z, Popovich PG, Satoskar AR, Whitacre CC, et al. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuro-inflammation. J Immunol 2013; 191:1043–1054.

    Article  CAS  Google Scholar 

  4. Gregory JL, Morand EF, Mckeown SJ, Ralph JA, Hall P, Yang YH, et al. Macrophage migration inhibitory factor induces macrophages recruitment via CC chemokine ligand-2. J Immunol 2006; 177:8072–8807.

    Article  CAS  Google Scholar 

  5. Lue H, Kleeman R, Calandra T, Roger T, Bernhagen J. Macrophage migration inhibitory factor: mechanisms of action & role in disease. Microbes Infect 2002; 4:449–460.

    Article  CAS  Google Scholar 

  6. Liu YH, Chen CC, Yang CM, Chen YJ, Tsai FJ. Dual effect of a polymorphism in the macrophage migration inhibitory factor gene is associated with new-onset Grave’s disease in a Taiwanese Chinese population. PLoS ONE 2014; 9.

  7. Becker H, Maaser C, Mickhols E, Doyng A. Relationship between serum level of macrophage migration inhibitory factor & the activity of antineutrophilic cytoplasmic antibody-associated vasculitides. Clin Rhaumatol 2006; 25:368.

    Article  Google Scholar 

  8. Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets 2010; 14:253–264.

    Article  CAS  Google Scholar 

  9. Erdogan M, Kulaksizoglu M, Ganidagli S, Berdeli A. Fas/FasL gene polymorphism in patients with Hashimoto’s thyroiditis in Turkish population. J Endocrinol Invest 2017; 40:82.

    Article  Google Scholar 

  10. Ates I, Yilmaz FM, Altay M, Yilmaz N, Berker D, Güler S. The relationship between oxidative stress and autoimmunity in Hashimoto’s thyroiditis. Eur J Endocrinol 2015; 173:791–799.

    Article  CAS  Google Scholar 

  11. Erdogan M, Kösenli A, Ganidagli S, Kulaksizoglu M. Characteristics of anemia in subclinical and overt hypothyroid patients. Endocr J 2012; 59:213–220.

    Article  CAS  Google Scholar 

  12. Halder T, Dastidar R, Bhattacharya S, Maji D. Prevalence of Hashimoto’s thyroiditis and its association with vitamin D deficiency in West Bengal, India. Br J Med Med Res 2016; 12:1–10.

    Article  Google Scholar 

  13. Han C, Xia X, Liu A, Zhang X, Zhou M, Xiong C, et al. Circulating betatrophin is increased in patients with overt and subclinical hypothyroidism. Biomed Res Int 2016; 2016:5090852.

    PubMed  PubMed Central  Google Scholar 

  14. Xue H, Yang Y, Zhang Y, Song S, Zhang L, Ma L, et al. Macrophage migration inhibitory factor interacting with Th17 cells may be involved in the pathogenesis of autoimmune damage in Hashimoto’s thyroiditis. Mediators Inflamm 2015; 2015:621072.

    Article  Google Scholar 

  15. Tian X, Ma J, Wang T, Tian J, Zheng Y, Peng R, et al. The long noncoding RNA IFNG-AS1 promotes T helper type 1 cells response in patients with Hashimoto’s thyroiditis. Sci Rep 2015; 5:17702.

    PubMed  PubMed Central  Google Scholar 

  16. Ayaz T, Sahin SB, Sahin OZ, Cure MC, Sumer F, Ilkkilic K, et al. Serum macrophage migration inhibitory factor levels in Hashimoto’s thyroiditis; a case control study. Thyroid Res 2014; 7:11.

    Article  Google Scholar 

  17. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. Hypothyroid symptoms and the likelihood of overt thyroid failure: a population-based case-control study. Eur J Endocrinol 2014; 171:593–602.

    Article  Google Scholar 

  18. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; 67:476–480.

    Article  CAS  Google Scholar 

  19. Ateş I, Altay M, Topçuoglu C, Yilmaz F. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch Endocrinol Metabol 2016; 60:95–100.

    Article  Google Scholar 

  20. Türemen EE, Çetinarslan B, Şahin T, Cantürk Z, Tarkun i. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis. Endocr J 2011; 58:349–354.

    Article  Google Scholar 

  21. Lupoli R, Dario Di Minno MN, Tortora A, Scaravilli A, Cacciapuoti M, Barba L, et al. Primary and secondary haemostasis in patients with subclinical hypothyroidism: effect of Levothyroxine treatment. J Clin Endocrinol Metab 2015; 100:2659–2665.

    Article  CAS  Google Scholar 

  22. Shatynska-Mytsyk L, Rodrigo R, Cioccocioppo D, Petrovic N, Lakusic N, Compostella L, et al. The impact of thyroid hormone replacement therapy on left ventricular diastolic function in patients with subclinical hypothyroidism. J Endocrinol Invest 2016; 39:709.

    Article  CAS  Google Scholar 

  23. Baskoy K, Ay SA, Altundag A, Kurt O, Salihoglu M, Deniz F, et al. Is there any effect on smell and taste functions with levothyroxine treatment in subclinical hypothyroidism? PLoS ONE 2016; 11:e0149979.

    Article  Google Scholar 

  24. Bae SC, Lee YH. Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis. Postgrad Med J 2017; 93:465–471.

    Article  Google Scholar 

  25. Feng X, Chen W, Xiao L, Gu F, Huang J, Tsao BP, Sun L. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus. Lupus 2017; 26:62–72.

    Article  CAS  Google Scholar 

  26. Sánchez-Zamora YI, Juarez-Avelar I, Vazquez-Mendoza A, Hiriart M, et al. Altered macrophage and dendritic cell response in Mif–/– mice reveals a role of Mif for inflammatory-Th1 response in type 1 diabetes. J Diabet Res 2016; 7053963.

  27. Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci 2015; 35:493–500.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Zagazig University, Zagazig, 44519, Egypt

    Ayman Abd Elrahman MN, MD & Nagwa S. Said

  2. Department of Clinical Pathology, Zagazig University, Zagazig, Egypt

    Azza Moustafa

Authors
  1. Ayman Abd Elrahman MN, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nagwa S. Said
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Azza Moustafa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ayman Abd Elrahman MN, MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elrahman, A.A., Said, N.S. & Moustafa, A. Serum macrophage migration inhibitory factor levels in Hashimoto’s thyroiditis. Egypt J Intern Med 31, 31–37 (2019). https://doi.org/10.4103/ejim.ejim_64_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_64_18

Keywords